Ikris Pharma Network Signs Exclusive Agreement with Santhera Pharmaceuticals for Distribution of DMD Medicine in India

Noida, India – 28 August 2025 – Ikris Pharma Network today announced the signing of an exclusive agreement with Santhera Pharmaceuticals (SIX: SANN) to distribute their medicine in India for the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged four years and older.

Under the agreement, Ikris Pharma Network will manage the distribution of DMD medicine in India for a five-year term. The product will initially be made available on a named-patient basis, with sales expected to begin in Q4 2025. In addition, Ikris Pharma Network is working to explore access through relevant government funding programs that support rare diseases, including DMD.

This agreement is part of Santhera’s wider global rollout strategy for DMD therapy, which has already secured distribution partnerships in Turkey and the Gulf Cooperation Council (GCC) countries.

Leadership Statements:

Praveen Sikri, Founder & CEO of Ikris Pharma Network, commented: “This collaboration with Santhera aligns with our focus on addressing unmet medical needs in the rare disease community. We look forward to leveraging our distribution network to help DMD patients in India access this life-changing treatment.”

Dario Eklund, Chief Executive Officer of Santhera, stated: “We are pleased to partner with Ikris Pharma Network in India, which is part of our wider strategy to increase global access to therapy for patients with DMD. Ikris’s expertise and dedication to ensuring rare disease drugs reach patients make them an ideal partner in the region.”

About Duchenne Muscular Dystrophy (DMD):

DMD is a rare, inherited neuromuscular disorder caused by mutations in the dystrophin gene, leading to progressive muscle weakness. Symptoms typically present in early childhood, and most patients lose ambulation in adolescence. While no cure is currently available, therapies and supportive care aim to slow progression and improve quality of life.

About Ikris Pharma Network:

Ikris Pharma Network is India’s leading named patient supply company, supporting access to therapies for rare diseases. With expertise in logistics, regulatory compliance, and patient access programs, Ikris enables physicians and patients to obtain therapies that are not available locally. The company has been actively involved in assisting Duchenne Muscular Dystrophy patients in India.

About Santhera Pharmaceuticals:

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on developing and commercializing treatments for rare neuromuscular diseases. The company holds an exclusive global license from ReveraGen for all indications of the medicine. For more information, visit www.santhera.com.

For further information, please contact:

Ikris Pharma Network

Praveen Sikri, CEO – info@ikrispharmanetwork.com 

Bharat Sikri, Global Project Manager  – https://ikrispharmanetwork.com/ 

Santhera Pharmaceuticals  – IR@santhera.com 

Disclaimer / Forward-Looking Statements:

This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially due to various factors. Readers should not place undue reliance on these statements. Neither Santhera nor Ikris undertakes any obligation to update such statements.